厄贝沙坦联合肾炎康治疗糖尿病肾病尿微量白蛋白的临床疗效  

Clinical effect by irbesartan combined with Shenyankang in the treatment of urine microalbumin in diabetic nephropathy

作　　者：刘孝猛[1] 刘劲松[1] 李萌[1] 刘丽颖[1] LIU Xiao-meng;LIU Jin-song;LI Meng(Department of Nephrology, Heilongjiang Provincial Hospital, Harbin 150036, China)

机构地区：[1]黑龙江省医院肾内科,150036

出　　处：《中国现代药物应用》2017年第11期98-99,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨治疗糖尿病肾病时采用厄贝沙坦联合肾炎康对尿微量白蛋白的影响。方法 98例糖尿病肾病患者,根据患者入院先后顺序进行编号,并采用奇偶配对的方式分为对比组和研究组,各49例。对比组患者采用厄贝沙坦治疗,研究组患者采用厄贝沙坦联合肾炎康治疗,比较两组患者的治疗效果及尿微量白蛋白含量。结果研究组患者治疗总有效率为89.80%,明显高于对比组的71.43%,差异具有统计学意义(P<0.05);治疗后,研究组患者尿微量白蛋白含量为(285.37±30.16)mg/24 h,明显低于对比组的(372.86±27.32)mg/24 h,差异具有统计学意义(P<0.05)。结论在治疗糖尿病肾病时选择厄贝沙坦联合肾炎康的方式能够有效提升治疗效果,降低尿微量白蛋白排出量。Objective To investigate influence by irbesartan combined with Shenyankang on urinemicroalbumin in diabetic nephropathy.Methods A total of98patients with diabetic nephropathy were divided byparity pairing of admission order into control group and research group,with49cases in each group.The controlgroup received irbesartan for treatment,and the research group received irbesartan combined with Shenyankangfor treatment.Comparison was made on curative effects and urine microalbumin contents between the two groups.Results The research group had obviously higher total effective rate in treatment as89.80%than71.43%in thecontrol group,and their difference had statistical significance(P<0.05).After treatment,the research group hadurine microalbumin content as(285.37±30.16)mg/24h,which was much lower than(372.86±27.32)mg/24h,and the difference had statistical significance(P<0.05).Conclusion Combination of irbesartan and Shenyankangin treating diabetic nephropathy can effectively improve curative effect and lower urine microalbumin dischargecontent.

关 键 词：糖尿病肾病 厄贝沙坦 肾炎康 尿微量白蛋白 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]